Geron Corporation
GERN
Jodie situation report
Geron Corporation's move is spreading beyond its market group.
No new filing conclusion is available. 8 of 15 group members are active now; 2 filing-linked outsiders are moving with the group, and 0 of 6 directly disclosed connections are confirming.
- At least 10 of 15 durable members become active together.
- Capital-flow agreement rises above 55%.
- ABBV remains aligned with the group in the next market snapshot.
Invalidation: The live read weakens if participation falls to 5 of 15 members or fewer.
Who this business touches
The relationships behind GERN
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
INCYIncyte CorporationpartnerMar 2, 2026 ▾
“nt Inc.; elritercept ( KER-050) in combination with ruxolitinib, by Keros Therapeutics; CK0804, an allogeneic T-regulatory cell agent, by Cellenkos, Inc.”
KROSFiling-linked namepartnerMar 2, 2026 ▾
“Other therapies currently in Phase 3 development in lower-risk MDS include elritercept (KER-050), a TGF-beta inhibitor, by Keros Therapeutics, Inc.; and Reblozyl (luspatercept) in non-transfusion-dependent lower-risk MDS patients, by BMS.”
BMYBristol-Myers Squibb CompanycompetitorMar 2, 2026 ▾
“In lower-risk MDS, RYTELO competes against a number of currently existing therapies, including ESAs (Epoetin alfa, Procrit; Darbepoetin alfa, Aranesp-Amgen) that are indicated for anemia; immunomodulators, such as Revlimid (lenalidomide) by Celgene Corporatio…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 4 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
GERN is currently a Participant in the organic co-movement group Biopharmaceuticals and Care. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.